1. Finland Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy

33.50
GBX
-1.50
(-4.29%)
8.32BMarket Cap
Mar 19Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
0.03
0.02
0.03
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.05
-0.05
-0.2
-0.32
-0.58
-0.5
-0.24
-0.28
-0.32
-0.4
-0.36
-0.27
-0.22
- -
Free Cash Flow per Basic Share
-0.03
-0.02
-0.24
-0.3
-0.51
-0.52
-0.21
-0.29
-0.34
-0.32
-0.28
-0.23
-0.15
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.03
-0.04
0.37
0.24
0.12
0.01
0.03
-0.03
0.04
-0.15
-0.17
-0.09
-0.15
0.06
Tangible Book Value per Share
-0.07
-0.08
0.34
0.24
0.12
- -
0.02
-0.04
0.03
-0.16
-0.18
-0.1
-0.16
0.05
Basic Weighted Avg Shares
30
30
30
31
37
40
56
60
66
72
85
96
121
133
Sales/Revenue/Turnover
- -
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-620
-135.54
-1,122.12
-1,019.22
- -
-103,426.32
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-1
-6
-10
-21
-20
-13
-17
-21
-29
-31
-26
-27
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-754
-150.55
-1,190
-1,064.92
- -
-105,715.79
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-1
-1
12
9
5
1
3
1
5
-1
-6
1
-3
20
LT Debt
1
2
1
2
2
2
3
3
3
11
9
8
14
9
Total Equity
-1
-1
11
8
5
- -
2
-2
3
-11
-15
-10
-19
12
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-103.56
-320.47
-785.84
-1,340.27
- -
- -
- -
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1
10
9
LT Borrowings
21
14
9
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
122
124
203
Market Capitalization
276
246
97

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
15
16
34
Cash, Cash Equivalents & STI
14
12
32
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
19
14
Payables & Accruals
- -
- -
- -
ST Debt
1
10
9
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-70.41%
-132.99%
89.58%
Free Cash Flow
15.43%
1.77%
-19.48%
Net Income, GAAP
21.8%
11.45%
5.16%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.27
2025
- -
- -
-0.22
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Juho Markku Jalkanen
Full Time Employees
33
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Joukahaisenkatu 6 B Turku FP Finland 20520
IPO Date
Nov 17, 2015
Website
faron.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies that target myeloid cells to activate anti-tumor immunity in hematological malignancies and solid tumors; its lead candidates include bexmarilimab, a first-in-class anti-CLEVER-1 humanized antibody reprogramming immunosuppressive tumor-associated macrophages to promote immune activation in combination with standard-of-care therapies such as azacitidine for relapsed/refractory and frontline high-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML), as well as Traumakine, an investigational intravenous interferon beta-1a therapy addressing cytokine release syndrome, ischemia, hyperinflammatory conditions, acute respiratory distress syndrome, and organ damage. Founded in 2003 and headquartered in Turku, Finland, the company operates globally with clinical trials conducted in Europe and the United States, targeting unmet needs in oncology and immune-mediated diseases through its proprietary platforms. Recent developments include positive Phase II data from the BEXMAB trial showing 43% complete remission rates and strong survival outcomes in high-risk MDS, FDA and EMA orphan drug designations for bexmarilimab in MDS with alignment on a registrational Phase II/III trial design using complete remission plus complete remission with equivocal recovery as a primary endpoint for accelerated approval potential, a EUR 12 million oversubscribed private placement of treasury shares in February 2025, an up to EUR 35 million convertible bond facility with Heights Capital Management including a EUR 15 million first tranche to repay prior debt and extend cash runway into 2026, Business Finland forgiveness of a EUR 1.3 million Traumakine-related R&D loan in July 2025, appointments of CEO Juho Jalkanen and Colin Bond to the Board in March 2025 and Chief Business Officer Ralph Hughes in May 2025, and oral presentations of bexmarilimab data at ESMO, ASCO, EHA, and MDS 2025 conferences alongside publication in The Lancet Haematology.